Barbara K Smith - JoVE Visualize

Showing results (51-60 of 53) with videos related to

Pageof 6

Sort By:

You have reached the last page of results.This site can display upto 53 results.

The Lancet. Neurology|November 17, 2023

Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trialPerry B Shieh, Nancy L Kuntz, James J Dowling, et al.

Journal of Neuromuscular Diseases|June 13, 2022

INCEPTUS Natural History, Run-in Study for Gene Replacement Clinical Trial in X-Linked Myotubular MyopathyJames J Dowling, Wolfgang Müller-Felber, Barbara K Smith, et al.

Ebiomedicine|December 12, 2023

Effects of gene replacement therapy with resamirigene bilparvovec (AT132) on skeletal muscle pathology in X-linked myotubular myopathy: results from a substudy of the ASPIRO open-label clinical trialMichael W Lawlor, Benedikt Schoser, Marta Margeta, et al.

Pageof 6

Showing results (51-60 of 53) with videos related to

Sort By:

Pageof 6

You have reached the last page of results.This site can display upto 53 results.

The Lancet. Neurology|November 17, 2023

Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trialPerry B Shieh, Nancy L Kuntz, James J Dowling, et al.

Journal of Neuromuscular Diseases|June 13, 2022

INCEPTUS Natural History, Run-in Study for Gene Replacement Clinical Trial in X-Linked Myotubular MyopathyJames J Dowling, Wolfgang Müller-Felber, Barbara K Smith, et al.

Ebiomedicine|December 12, 2023

Effects of gene replacement therapy with resamirigene bilparvovec (AT132) on skeletal muscle pathology in X-linked myotubular myopathy: results from a substudy of the ASPIRO open-label clinical trialMichael W Lawlor, Benedikt Schoser, Marta Margeta, et al.

Pageof 6